Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
2012; Oxford University Press; Volume: 104; Issue: 17 Linguagem: Inglês
10.1093/jnci/djs317
ISSN1460-2105
AutoresErin J. Aiello Bowles, Robert Wellman, Heather Spencer Feigelson, Adedayo A. Onitilo, Andrew N. Freedman, Thomas Delate, Larry A. Allen, Larissa Nekhlyudov, Katrina A.B. Goddard, Robert L. Davis, Laurel A. Habel, Marianne Ulcickas Yood, Catherine A. McCarty, David J. Magid, Edward H. Wagner, Pharmacovigilance Study Team,
Tópico(s)Cancer Treatment and Pharmacology
ResumoBackgroundClinical trials demonstrated that women treated for breast cancer with anthracycline or trastuzumab are at increased risk for heart failure and/or cardiomyopathy (HF/CM), but the generalizability of these findings is unknown. We estimated real-world adjuvant anthracycline and trastuzumab use and their associations with incident HF/CM.
Referência(s)